Q4 2024 Earnings Call Transcript March 20, 2025 Operator: Ladies and gentlemen, thank you for standing by. My name is Jale, and I will be your conference operator today. At this time, I would like to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The combined companies will operate under the name Kalaris Therapeutics, Inc. and expects to report initial data from part 1 ...

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 19.5% in the ...

Protara Therapeutics (NASDAQ:TARA – Get Free Report) and Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will ...

NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...

Peeples Cancer Institute at Hamilton Medical Center has expanded access to the latest in cancer research for patients in ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

The NIH announced the beginning of a phase 1 first-in-human trial of a vaccine for Lassa fever, a potentially fatal viral hemorrhagic disease for which there is no approved vaccine or treatment.

Data from the SAPPHIRE study formed the basis of Scholar Rock's U.S. Food and Drug Administration request to approve apitegromab for SMA.

Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical ...